Research Library

Special purpose acquisition companies (SPACs) have experienced a massive surge in popularity over the last year. How do SPACs work, and what are some of the tax implications that investors may overlook? Public finance fellow Joyce Beebe explains on the Baker Institute Blog: https://bit.ly/3t5eMH8

Restrictions in Texas' medical cannabis law keep most of the state's patients from participating. Our survey of 2,866 Texas residents who use medical cannabis sought to gain insight into the needs and experiences of this population.

Fellow Katharine Neill Harris testified before the U.S. House Judiciary Committee on the failed war on drugs and solutions based on racial justice and harm reduction.

Effective drug policy requires acceptance that, for better or worse, licit and illicit drug use is part of our world. The authors recommend several steps the federal government can take to facilitate more pragmatic and effective drug policy at all levels of government.

The authors examine recent trends in vaping, research on its effectiveness for smoking cessation, the role of industry marketing and policy responses to increased use.

Products containing hemp extracts high in CBD are gaining mainstream popularity, acceptance and federal legality. In this article, Lisa Pittman, nonresident fellow in drug policy, focuses on litigation issues particular to hemp.

In recent years public opinion surveys have found that a consistent and increasing percentage of Texans support marijuana reform, but this support has not translated into policy change. The authors explain why it should.

By providing regulated and safe access to medical cannabis to people with demonstrated need, the Texas Legislature can provide justified relief, help reduce the opioid epidemic, and save Texas millions of dollars, write the authors.

Houston and Harris County area law enforcement leaders weigh in on the need for drug policy reforms in the United States.

The Commission on Combatting Drug Addiction and the Opioid Crisis appointed by President Trump released its report on Monday, July 31. Drug policy fellow Katharine Neill Harris assesses the commission's recommendations in the Baker Institute Blog.